Excalibur Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.99M | Sell |
32,865
-31
| -0.1% | -$1.81K | 0.72% | 38 |
|
|
2025
Q4 | $1.77M | Buy |
32,896
+2,037
| +7% | +$98K | 0.64% | 42 |
|
|
2025
Q3 | $1.39M | Sell |
30,859
-822
| -3% | -$38.4K | 0.51% | 58 |
|
|
2025
Q2 | $1.47M | Sell |
31,681
-1,041
| -3% | -$51.1K | 0.55% | 50 |
|
|
2025
Q1 | $2M | Buy |
32,722
+273
| +0.8% | +$15.9K | 0.78% | 33 |
|
|
2024
Q4 | $1.84M | Sell |
32,449
-410
| -1% | -$22.9K | 0.73% | 34 |
|
|
2024
Q3 | $1.7M | Buy |
32,859
+1,218
| +4% | +$57.1K | 0.65% | 39 |
|
|
2024
Q2 | $1.31M | Buy |
31,641
+6,199
| +24% | +$277K | 0.54% | 50 |
|
|
2024
Q1 | $1.38M | Buy |
25,442
+3,319
| +15% | +$169K | 0.58% | 44 |
|
|
2023
Q4 | $1.14M | Buy |
22,123
+1,086
| +5% | +$57K | 0.53% | 50 |
|
|
2023
Q3 | $1.22M | Buy |
21,037
+1,161
| +6% | +$71.1K | 0.63% | 39 |
|
|
2023
Q2 | $1.27M | Buy |
19,876
+55
| +0.3% | +$3.69K | 0.65% | 38 |
|
|
2023
Q1 | $1.37M | Buy |
19,821
+308
| +2% | +$21.7K | 0.71% | 35 |
|
|
2022
Q4 | $1.4M | Sell |
19,513
-588
| -3% | -$44.3K | 0.73% | 35 |
|
|
2022
Q3 | $1.43M | Buy |
20,101
+13
| +0.1% | +$943 | 0.8% | 31 |
|
|
2022
Q2 | $1.55M | Sell |
20,088
-3,833
| -16% | -$292K | 0.8% | 30 |
|
|
2022
Q1 | $1.75M | Sell |
23,921
-91
| -0.4% | -$6.11K | 0.76% | 35 |
|
|
2021
Q4 | $1.5M | Buy |
24,012
+3,785
| +19% | +$222K | 0.6% | 41 |
|
|
2021
Q3 | $1.2M | Buy |
20,227
+1,270
| +7% | +$83.6K | 0.52% | 53 |
|
|
2021
Q2 | $1.27M | Buy |
18,957
+200
| +1% | +$13K | 0.57% | 46 |
|
|
2021
Q1 | $1.18M | Buy |
18,757
+898
| +5% | +$55.9K | 0.58% | 45 |
|
|
2020
Q4 | $1.11M | Buy |
17,859
+423
| +2% | +$26K | 0.6% | 43 |
|
|
2020
Q3 | $1.05M | Sell |
17,436
-166
| -0.9% | -$9.99K | 0.64% | 41 |
|
|
2020
Q2 | $1.03M | Sell |
17,602
-245
| -1% | -$14.7K | 0.69% | 38 |
|
|
2020
Q1 | $995K | Buy |
17,847
+153
| +0.9% | +$9.35K | 0.77% | 30 |
|
|
2019
Q4 | $1.14M | Buy |
17,694
+230
| +1% | +$13.2K | 0.74% | 33 |
|
|
2019
Q3 | $886K | Buy |
17,464
+283
| +2% | +$13.3K | 0.8% | 35 |
|
|
2019
Q2 | $779K | Buy |
17,181
+1,446
| +9% | +$67.4K | 0.72% | 38 |
|
|
2019
Q1 | $751K | Sell |
15,735
-10
| -0.1% | -$498 | 0.71% | 39 |
|
|
2018
Q4 | $818K | Sell |
15,745
-780
| -5% | -$41.9K | 0.83% | 32 |
|
|
2018
Q3 | $1.03M | Sell |
16,525
-550
| -3% | -$32.6K | 0.88% | 31 |
|
|
2018
Q2 | $945K | Hold |
17,075
| – | – | 0.75% | 39 |
|
|
2018
Q1 | $1.08M | Sell |
17,075
-150
| -0.9% | -$9.65K | 0.88% | 33 |
|
|
2017
Q4 | $1.06M | Sell |
17,225
-540
| -3% | -$33.8K | 0.89% | 30 |
|
|
2017
Q3 | $1.13M | Buy |
17,765
+3,420
| +24% | +$200K | 0.96% | 29 |
|
|
2017
Q2 | $799K | Buy |
14,345
+300
| +2% | +$16.3K | 0.72% | 36 |
|
|
2017
Q1 | $764K | Sell |
14,045
-500
| -3% | -$27.4K | 0.68% | 35 |
|
|
2016
Q4 | $850K | Hold |
14,545
| – | – | 0.77% | 33 |
|
|
2016
Q3 | $784K | Sell |
14,545
-1,050
| -7% | -$67.4K | 0.74% | 31 |
|
|
2016
Q2 | $1.15M | Sell |
15,595
-5
| -0% | -$353 | 0.99% | 24 |
|
|
2016
Q1 | $997K | Sell |
15,600
-15
| -0.1% | -$946 | 0.89% | 26 |
|
|
2015
Q4 | $1.07M | Sell |
15,615
-75
| -0.5% | -$4.96K | 1% | 27 |
|
|
2015
Q3 | $929K | Hold |
15,690
| – | – | 0.93% | 28 |
|
|
2015
Q2 | $1.04M | Sell |
15,690
-168
| -1% | -$11.1K | 0.98% | 25 |
|
|
2015
Q1 | $1.02M | Sell |
15,858
-1,080
| -6% | -$67.6K | 0.99% | 25 |
|
|
2014
Q4 | $1M | Sell |
16,938
-1,261
| -7% | -$71.1K | 1.01% | 25 |
|
|
2014
Q3 | $931K | Sell |
18,199
-571
| -3% | -$28.5K | 0.96% | 25 |
|
|
2014
Q2 | $911K | Sell |
18,770
-35
| -0.2% | -$1.73K | 0.95% | 24 |
|
|
2014
Q1 | $977K | Sell |
18,805
-1,360
| -7% | -$72.4K | 1.07% | 20 |
|
|
2013
Q4 | $1.07M | Sell |
20,165
-5,650
| -22% | -$288K | 1.17% | 21 |
|
|
2013
Q3 | $1.2M | Buy |
25,815
+150
| +0.6% | +$6.58K | 1.4% | 19 |
|
|
2013
Q2 | $1.15M | Buy |
+25,665
| New | +$1.11M | 1.42% | 17 |
|
Other funds holding BMY
VCM
VPM
Excalibur Management's BMY Position: Q1 2026 in Review
Excalibur Management reduced its Bristol-Myers Squibb (BMY) stake by 0.09% in Q1 2026, selling an estimated $1.81K and leaving 32,865 shares worth $1.99M. The position accounts for 0.72% of the portfolio, ranked #38.
Excalibur Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $2M in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Excalibur Management held 32,865 shares of Bristol-Myers Squibb worth $1.99M as of Q1 2026.
- Excalibur Management sold 31 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.81K.
- Bristol-Myers Squibb made up 0.72% of Excalibur Management's portfolio in Q1 2026, its #38 holding.
- Excalibur Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
- Excalibur Management's Bristol-Myers Squibb position peaked at $2M in Q1 2025.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Excalibur Management's 13F filing for Q1 2026, filed 5 May 2026.